A Study of MGC028 in Participants With Advanced Solid Tumors

The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9. The main question the study aims to answer is: * What types of side effects will participants experience when receiving MGC028? * Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with a

Trial Details

NCT ID
NCT06723236
Phase
PHASE1
Sponsor
MacroGenics
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • MGC028
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Participants in dose escalation or supplemental cohorts must have histologically proven unresectable, locally advanced or metastatic solid tumor li…
  • Participants in expansion cohorts must have either
  • NSCLC adenocarcinoma with
  • progression on or following anti-PD-1/PD-L1 inhibitor, unless contraindicated

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →